"Tizona is pursuing first-in-class cancer immunotherapies that could make an important difference in oncology by helping patients who don't respond to current checkpoint inhibitors," said Gilead Chief Executive Daniel O'Day.Gilead's stock, which slipped 0.4% in premarket trading, has rallied 20.2% year to date through Monday, while the iShares Nasdaq Biotechnology ETF